There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Scotoma Perimetry Oculomotor Training
NCT05456581
Recruiting
The proposed research is relevant to public health because a greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the NEI to support research on visual disorders, mechanisms of visual function and preservation of sight. Declines in vision are particularly common in older adults and thus in... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
01/24/2024
Locations: UAB, Birmingham, Alabama
Conditions: Macular Degeneration, Central Visual Impairment
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
An Exercise Intervention to Improve Overall Brain Health
NCT06035094
Recruiting
The goal of this clinical trial is to test the effects of 10 weeks of exercise on overall brain health, reduction in blood pressure, and the number of blood vessels in the back of the eyes in patients with hypertension and have a body mass index ≥ 25 kg/m2. The main question[s] it aims to answer are: To test the effect of moderate vs intensive exercise on Brain Care Score outcomes. To ascertain the differential impact of moderate vs high intensity exercise in reducing hypertension and its downs... Read More
Gender:
All
Ages:
Between 35 years and 65 years
Trial Updated:
01/22/2024
Locations: UAB, Birmingham, Alabama
Conditions: Brain Care Score, Exercise, Hypertension, BMI
Register for Updates
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630
Recruiting
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/22/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
Register for Updates
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
NCT04203316
Recruiting
This trial studies the side effects of enasidenib and to see how well it works in treating patients with acute myeloid leukemia that has come back after treatment (relapsed) or has been difficult to treat with chemotherapy (refractory). Patients must also have a specific genetic change, also called a mutation, in a protein called IDH2. Enasidenib may stop the growth of cancer cells by blocking the mutated IDH2 protein, which is needed for cell growth.
Gender:
All
Ages:
Between 24 months and 21 years
Trial Updated:
01/19/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT03321045
Recruiting
Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship between 89Zr-trastuzumab uptake and response... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: The Kirklin Clinic, Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates
A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
NCT04572243
Recruiting
The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.
Gender:
All
Ages:
2 years and above
Trial Updated:
01/18/2024
Locations: Children's of Alabama / University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Epilepsies, Myoclonic
Register for Updates
Study of Treatment for HPV16+ ASC-US or LSIL
NCT03913117
Recruiting
Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine
Gender:
Female
Ages:
19 years and above
Trial Updated:
01/18/2024
Locations: UAB | The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: ASC-US, LSIL
Register for Updates
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT03728985
Recruiting
Prospective, non-randomized, , multicenter study with two independent arms: Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
01/18/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Thoracoabdominal Aortic Aneurysm
Register for Updates
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
NCT05410509
Recruiting
Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Renal Cell Carcinoma (RCC)
Register for Updates
Compression Nail for Tibiocalcaneal Arthrodesis
NCT03780452
Recruiting
The purpose of this study is to determine the clinical efficacy of a novel dynamic compression intramedullary nail for tibiotalocalcaneal (TTC) arthrodesis
Gender:
All
Ages:
Between 18 years and 110 years
Trial Updated:
01/18/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Subtalar Arthritis, Ankle Arthritis
Register for Updates
Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure
NCT04629014
Recruiting
This study proposes to quantify and describe the quality of life of children with intestinal failure, and to identify the medical and socio-economic factors that impact this quality of life, using data from multiple multidisciplinary intestinal failure centers across the United States and Canada specializing in the care of these participants.
Gender:
All
Ages:
Between 6 months and 25 years
Trial Updated:
01/17/2024
Locations: Children's of Alabama, Birmingham, Alabama
Conditions: Pediatric Intestinal Failure
Register for Updates